The arrival of the influenza-like illness season has coincided with another rise in COVID-19 cases, as the pandemic continues across the globe. Check out our article on the top 3 considerations during this unusual flu season.
Many tests provide an answer about the presence of SARS-CoV-2. However, a new 30-study systematic review and meta-analysis published in the Journal of Infection suggests that some patients may be infected by more than one pathogen. How can you test for multiple respiratory pathogens when time is of the essence?
During this webinar, QIAGEN Chief Medical Officer Dr. Davide Manissero will discuss the role of multiplex respiratory PCR testing in the ongoing COVID-19 pandemic and how QIAGEN ramped up development efforts to be the first syndromic solution on the market. The importance of time to diagnosis and potential for co-infections as we approach the 2020-2021 influenza season will be discussed.
To support the efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN developed the QIAstat-Dx Respiratory SARS-CoV-2 Panel. This version of our multiplex syndromic cartridge detects and differentiates* 21 respiratory targets, including SARS-CoV-2 from Nasopharyngeal swabs (NPS) eluted in universal transport media (UTM).